Altus Reports Last Patient Visit of Phase III Cystic Fibrosis Trial
Posted on: Monday, 16 June 2008, 12:01 CDT
Altus Pharmaceuticals has announced the completion of the last patient visit of the Trizytek Phase III efficacy trial. In this trial, Altus is evaluating the efficacy of an oral, non-porcine enzyme replacement therapy for cystic fibrosis patients with exocrine pancreatic insufficiency.
The Digest efficacy trial tested a one capsule per-meal dosing regimen and will study fat, protein and carbohydrate absorption in cystic fibrosis patients with exocrine pancreatic insufficiency.
In parallel with the efficacy trial, Altus is conducting a long-term safety study to evaluate Trizytek following one year of open-label treatment.
Georges Gemayel, president and CEO of Altus, said: "Completing the last patient visit of the Phase III efficacy trial marks an important milestone in the development of Trizytek. This news confirms that we are on track to report top-line Trizytek efficacy data in the third quarter of 2008."
Source: Datamonitor
Related Articles
- AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of Its Phase 3 Program With Cetrorelix in Benign Prostatic Hyperplasia
- Altus's Phase III Efficacy Trial of Trizytek Meets Primary Endpoint
- Altus Pharmaceuticals Announces Achievement of Primary Endpoint in Phase 3 Efficacy Trial of Trizytek for Cystic Fibrosis Patients With Pancreatic Insufficiency
- Altus Pharmaceuticals Reports Last Patient Visit Of Trizytek(TM) Phase 3 Efficacy Trial
- AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial With Cetrorelix in Benign Prostatic Hyperplasia
- Largest Cervical Cancer Vaccine Efficacy Trial Shows CERVARIX(R) Provides Excellent Protection Against Lesions Caused By Most Common Cancer-Causing Virus Types
- AVAC Applauds Commencement of First HIV Vaccine Efficacy Trial in Africa
- Alexion Pharmaceuticals Reports Positive Phase III Results for Eculizumab From Pivotal TRIUMPH Efficacy Trial in Paroxysmal Nocturnal Hemoglobinuria Patients
- Alexion Completes Patient Treatment in Its Phase III Pivotal TRIUMPH Efficacy Trial of Eculizumab in PNH Patients
- Alexion Completes Randomization of Its Phase III Pivotal TRIUMPH Efficacy Trial of Eculizumab in PNH Patients
 |
 |
User Comments (0)
RSS Feeds